Phenylephrine CRI

Pure α₁-adrenergic agonist with essentially no β-receptor activity at clinical doses. Acts at vascular α₁ receptors to produce arteriolar vasoconstriction; the resulting rise in systemic vascular resistance increases MAP. Lack of β-1 inotropic stimulation means cardiac output may not rise (and can fall in patients with impaired contractility). Lack of β-2 effect means no bronchodilation. Reflex bradycardia from baroreceptor response is common. Onset within 1–2 min IV; duration ~5–20 min after stop.

Open calculator →

Clinical background

Phenylephrine is a selective α₁-adrenergic agonist with no clinically relevant β activity. It produces arteriolar vasoconstriction without the tachycardia or arrhythmogenicity that accompanies norepinephrine or epinephrine. The clinical pivot is reflex bradycardia: the strong MAP rise from pure α₁ activation triggers a baroreceptor-mediated slowing of heart rate, which is undesirable in most shock states but is exactly the property that makes phenylephrine attractive in specific settings where tachycardia must be avoided. In general vet ICU practice phenylephrine sees less use than norepinephrine; in anesthesia and in patients with limited tolerance for additional tachyarrhythmia it has a clear role.

Pharmacology

Synthetic α₁ agonist, structurally similar to norepinephrine but lacking the catechol hydroxyl groups that confer β-receptor affinity. The receptor profile produces:

• Strong arteriolar vasoconstriction (α₁), raising systemic vascular resistance and MAP. The vasoconstriction is more pronounced in the splanchnic and renal beds than with norepinephrine because the β₂-mediated counter-regulation is absent.
• Reflex bradycardia. Rising MAP activates aortic and carotid baroreceptors, increasing parasympathetic tone and decreasing sympathetic outflow to the heart. Rate usually drops 10–20% with effective infusion. In patients who are already bradycardic or whose stroke volume depends on rate, this is a problem.
• No inotropic support. Without β₁ activity, phenylephrine offers nothing to cardiac contractility; in low-output states, cardiac output may fall as afterload rises with no inotropic offset.
• No β₂ vasodilation. Useful where a paradoxical β₂-mediated MAP drop is a concern (acepromazine-premedicated patients on epinephrine, classically).

Onset is within 1–2 minutes IV; the half-life is short (5–15 minutes), making titration responsive. Hepatic metabolism with renal excretion.

Indications

Primary use cases:

• Anesthesia-induced hypotension when tachycardia is undesirable or already present. Inhalant-induced vasodilation that has not responded to lightening the plane and a fluid bolus, in a patient whose heart rate is at the upper end of acceptable. Phenylephrine corrects the MAP without making rate worse.
• Hypotension in dynamic LVOT obstruction in feline HCM. Cats with hypertrophic obstructive cardiomyopathy can deteriorate during anesthesia when MAP falls; the dropping afterload exacerbates the dynamic outflow tract obstruction. Phenylephrine raises afterload, reduces the gradient, and restores stroke volume. This is one of the few settings where it is the first choice rather than norepinephrine.
• Acepromazine-related hypotension. Acepromazine is an α-adrenergic antagonist; epinephrine in this setting can produce paradoxical hypotension through unopposed β₂ activity (“epinephrine reversal”). Phenylephrine, pure α₁, gives a predictable MAP response. Norepinephrine works in this setting too, with somewhat blunted response from the α-antagonism on board.
• Septic or hemorrhagic shock as a temporizing measure when a definitive vasopressor cannot be prepared immediately. Phenylephrine is shelf-stable in ampules and can be drawn up and given as a bolus or short CRI while norepinephrine is being mixed. It is not a substitute for norepinephrine in sustained shock care.

Phenylephrine is not a first-line vasopressor for most vet ICU shock states. The lack of inotropic support and the reflex bradycardia are clinically meaningful disadvantages compared to norepinephrine. Reach for it when the specific pharmacology (no rate effect, no inotropy, predictable α₁ response) is what is wanted, not as a generic pressor.

Dosing

• Dogs and cats, hypotension CRI: 0.5–3 µg/kg/min, titrated against MAP.
• Initial rate: 0.5–1 µg/kg/min.
• Caution above: 2 µg/kg/min. Reflex bradycardia and excessive vasoconstriction (cold peripheries, splanchnic hypoperfusion) become more apparent. Higher doses are reported but should prompt reassessment of whether phenylephrine is the right drug for this patient.
• Intermittent IV bolus: 1–10 µg/kg slowly, for transient hypotension during anesthesia where a CRI is not warranted. Effect lasts 5–15 minutes.

Cat dosing uses the same range as dogs. Start at the lower end in cats with HCM, in whom the goal is restoring afterload rather than aggressive MAP elevation.

Administration

Stock concentration in the US is 10 mg/mL (Neo-Synephrine and equivalents), typically a 1 mL ampule. For CRI delivery, the stock is diluted into 0.9% sodium chloride or 5% dextrose. The InfusionFox calculator preselects three weight-banded preparations (100, 40, or 20 µg/mL) so the pump rate stays in the precision range across patient size.

Peripheral administration is acceptable. Extravasation risk exists (pure α₁ vasoconstriction) but is lower than with norepinephrine because the duration of action is shorter and the typical infusion duration is briefer. If extravasation occurs, the same management approach applies (stop, aspirate, remove the catheter, consider phentolamine infiltration).

Phenylephrine is compatible with most IV fluids and most co-administered drugs. Do not mix with alkaline solutions or iron-containing fluids, which inactivate the catecholamine-like ring.

Drug interactions

• MAO inhibitors and tricyclic antidepressants potentiate the vasopressor effect. Use lower starting doses and titrate carefully.
• α-adrenergic blockers (acepromazine, phenoxybenzamine) blunt the vasopressor response. In acepromazine-premedicated patients the response is reduced but still useful.
• Halogenated inhalant anesthetics sensitize the myocardium and may potentiate any arrhythmia from concurrent infusions; arrhythmia risk with phenylephrine is lower than with epinephrine but is not zero.
• β-blockers can amplify the reflex bradycardia and may produce hemodynamically significant slowing; reassess rate response carefully when both are on board.
• Atropine or glycopyrrolate can be used to attenuate reflex bradycardia if it becomes hemodynamically limiting, though this somewhat negates the rationale for choosing phenylephrine in the first place.

Adverse effects

• Reflex bradycardia: the most common dose-limiting effect. Heart rate falls 10–20% with effective infusion; if it falls further than this, reduce the dose.
• Excessive vasoconstriction: cold peripheries, decreased capillary refill, splanchnic hypoperfusion (rising lactate that does not correct, ileus, oliguria). More common at doses above 2 µg/kg/min and with prolonged infusion.
• Hypertension if not titrated against a specific MAP target. The pure α₁ response is more linear with dose than norepinephrine’s mixed activity, so MAP can overshoot if titration is sloppy.
• Tissue necrosis at the infusion site with extravasation. Less common than with norepinephrine but reported.
• Decreased cardiac output in patients with limited ventricular function. The rising afterload is not offset by inotropic support; if stroke volume falls, MAP may not even rise as expected.

Monitoring

• Continuous or frequent blood pressure, ideally MAP. Titrate against a specific MAP target.
• Continuous ECG for rate and rhythm. The expected response is mild rate slowing; substantial bradycardia is dose-limiting.
• Peripheral perfusion markers: extremity temperature, mucous membrane color, capillary refill. Cold extremities at high MAP suggest excessive vasoconstriction.
• Lactate trend in shock patients, particularly looking for splanchnic hypoperfusion (rising lactate despite achieved MAP target).
• Urine output as a perfusion marker.
• The infusion site at every check, with documented inspection.

Weaning

Reduce in 0.25–0.5 µg/kg/min increments every 10–15 minutes against MAP. Abrupt cessation can produce rebound hypotension, particularly after extended infusions. For brief intraoperative use, abrupt cessation is usually well tolerated once the underlying cause (anesthetic plane, surgical stimulus) has been corrected.

Sources

• Plumb’s Veterinary Drugs, phenylephrine monograph (current edition).
• Hart S, Silverstein DC. Catecholamines. In: Silverstein DC, Hopper K, eds. Small Animal Critical Care Medicine. 3rd ed. Elsevier; 2023:855–859. Chapter 147; Table 147.1.
• Côté E, MacDonald KA, Meurs KM, Sleeper MM, eds. Feline Cardiology. Wiley-Blackwell; 2011. (Phenylephrine use in feline obstructive HCM.)